The thesis

ANI Pharmaceuticals manufactures branded and generic drugs, including Cortrophin gel and the ILUVIEN and YUTIQ eye implants. Revenue grew 25.9% year over year, a real growth signal in a specialty and generic pharma niche. But the reported gross margin of 6523% and net margin of 1082% are not credible operating figures. They point to a one-time gain, an accounting distortion, or a data error, not sustainable profitability. The composite conviction score of 34/100 sits far below what the HIGH tier label implies, and that gap is the central contradiction here, not the growth number.

Why now

Analyst consensus is BUY and DCF intrinsic value is put at $968, but no current share price is given here to test that gap. The macro overlay cited is Iran sanctions escalation, which has no direct linkage to a specialty pharma manufacturer, and the risk-off rotation signal is marked inactive despite carrying a +5 weight — an internal inconsistency worth resolving before acting.

What to watch

Watch the next quarterly filing for normalized gross and net margins, since the reported 6523% and 1082% figures cannot persist and will revert toward industry norms. Track whether the 25.9% revenue growth rate holds as Cortrophin gel and the injectables portfolio scale, and whether the composite conviction score moves toward or away from the HIGH tier label over the next one to two quarters.

Key risks

The margin figures need verification; if they reflect a legal settlement, asset sale, or licensing payment, normalized profitability could look very different next quarter. A 34/100 composite score against a HIGH tier label suggests the rating framework and the underlying financial quality are not aligned, raising the risk that the BUY consensus is pricing in growth that the margin data cannot support. Broader sanctions-driven market volatility could pressure healthcare multiples generally, independent of ANI's own fundamentals.

Theme exposure